Karen Rabin
Karen Rabin

Karen Rabin

MD, PhD

Pediatric hematologist-oncologist
Director, Pediatric Blood Cancer Program
Leukemia doctor and researcher, cyclist and nature lover

Contact me

Contact me

Dr. Karen Rabin is a pediatric hematologist-oncologist who cares for children with leukemia and other blood cancers.

Rabin's research focuses on improving outcomes for children and adolescents with acute lymphoblastic leukemia (ALL). Her laboratory research investigates ALL in children with Down syndrome, who have a higher risk of developing leukemia and an increased risk of relapse and treatment complications compared with other children. Her lab seeks to learn why these patients are at increased risk, what genetic alterations are unique to their leukemia and how to use this information to cure more children. She also holds leadership roles in ALL-related clinical trials (studies of promising treatments) being carried out by the Children's Oncology Group and is involved in research collaborations looking at how to improve outcomes across all populations of children and adolescents with ALL.

Rabin earned her medical degree at UCSF, where she also completed a residency in pediatrics. She completed a fellowship in pediatric hematology-oncology at Stanford University, training at Lucile Packard Children's Hospital Stanford. She has a master's degree in medical law and ethics from King's College London and a doctorate in clinical investigation from Baylor College of Medicine.

In her free time, Rabin likes to run, cycle, hike, cook and travel.

  • Board Certifications

    American Board of Pediatrics/Hematology-Oncology, Pediatric Hematology-Oncology

    American Board of Pediatrics, Pediatrics

  • Fellowships

    Stanford University Hematology Fellowship Program, Pediatric Hematology-Oncology

  • Residencies

    UCSF Graduate Medical Education, Pediatrics

  • Internship

    UCSF Graduate Medical Education, Pediatrics

  • Degree

    MD, University of CA at San Francisco

My patients inspire me with their strength and resilience. It is an honor to care for them and their families.

Where I see patients (2)

    Selected research

    See all research
    Decorative Caduceus

    Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...

    Will compare in a randomized manner the post-induction 5-year EFS for children and young adults with High Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) treated with a modified Berlin-Frankfurt-Münster (mBFM) chemo-immunoth...

    Recruiting

    More about this study
    Decorative Caduceus

    A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatu...

    Will be assessed in children, adolescents, and young adults <25 years old with newly-diagnosed Ph+ (BCR::ABL1-rearranged) B acute lymphoblastic leukemia (B-ALL) who are treated with a modified Berlin-Frankfurt-Münster (mBFM) chemo...

    Recruiting

    More about this study
    Decorative Caduceus

    A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute ...

    Summary statistics will be used to characterize the study populations on CHC outcomes. Quantitative data (number of comorbidities) will be summarized using descriptive statistics and correlational techniques. Will use pooled logis...

    Recruiting

    More about this study
    Decorative Caduceus

    A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With...

    MRD negative Rem-2 be defined as Rem-2 (i.e., achievement of MRD < 1% blasts by flow cytometry and resolution of extramedullary disease (for CNS disease, requires CNS 1) ) and bone marrow with MRD < 0.01% by flow cytometry. MRD ne...

    Recruiting

    More about this study
    See all clinical trials

    Contact me

    Translation, please

    We have interpreters for Cantonese, Mandarin, Spanish, Russian, American Sign Language and more.

    Request an interpreter

    Share